Sign In
Buy TVGN
$9.06
+0.590 (+6.97%)
At Close: Jun 03, 2026
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
12:30pm, Thursday, 28'th May 2026
WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
12:15pm, Thursday, 21'st May 2026
WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding L
Letter to Shareholders from CEO Dr. Ryan Saadi
12:15pm, Monday, 18'th May 2026
Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth, and evaluation of revenue-generating acquisitions.
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
11:45am, Tuesday, 12'th May 2026
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
11:50am, Monday, 27'th Apr 2026
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiat
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
12:45pm, Thursday, 26'th Mar 2026
Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices Target CRO operates acr
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
02:20pm, Wednesday, 25'th Mar 2026
WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock
Tevogen Bio (TVGN) to Release Quarterly Earnings on Wednesday
02:48am, Wednesday, 25'th Mar 2026
Tevogen Bio (NASDAQ: TVGN - Get Free Report) will likely be releasing its results before the market opens on Wednesday, April 1st. Analysts expect Tevogen Bio to post earnings of ($0.0620) per share f
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
12:22pm, Wednesday, 18'th Mar 2026
WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevo
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
02:45pm, Friday, 13'th Mar 2026
Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value
WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence plat
WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the co
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
07:45am, Monday, 09'th Mar 2026
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business v
Letter to Shareholders from CEO Dr. Ryan Saadi
03:40pm, Friday, 06'th Mar 2026
WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN).
Tevogen Bio Explores Buyout To Boost Generics Platform
12:42pm, Friday, 06'th Mar 2026
Tevogen Bio Holdings (NASDAQ: TVGN) shares are wobbling on Friday as the company is advancing its generics strategy through a signed letter of intent to evaluate a potential acquisition of Apozeal Pha
